Trials / Not Yet Recruiting
Not Yet RecruitingNCT06437951
to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection
A Randomized, Double-blind, Placebo-controlled, Single/Multiple-dose, Phase 1 Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics After Intravenous DWP14012 Injection in Healthy Participants
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fexuprazan Injection | 20/40/80 mg |
| DRUG | Fexuprazan Injection placebo | 20/40/80 mg |
| DRUG | Fexuprazan Injection_part 2 | 20mg |
| DRUG | Fexuprazan Injection_part 3 | 40mg |
| DRUG | Fexuprazan tablet | 40mg |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2025-01-01
- Completion
- 2025-05-01
- First posted
- 2024-05-31
- Last updated
- 2024-06-03
Source: ClinicalTrials.gov record NCT06437951. Inclusion in this directory is not an endorsement.